MESI mCARE Home: a comprehensive system solution for telemonitoring risk patient groups

The MESI mCARE (Home) operation directly eliminates the consequences of COVID-19. For this purpose, it develops medical equipment and comprehensive system solutions for monitoring risk patient groups with telemedicine, diagnostics, AI and smart data storage. This will increase the accessibility of risk patients to health services unavailable during the pandemic.

The MESI mCARE (Home) operation aims to make an impact with faster and more available treatments and shorter waiting times in both public and private healthcare. This will contribute to timely identification, treatment and management of chronic conditions, and thus better outcomes for the patients.

The MESI mCARE (Home) product puts the needs of risk patient groups at the centre. As a priority, it focuses on the issue of limited access to regular medical care: it enables faster and more accurate patient referrals, which results in shorter waiting times and lower treatment costs. It revolutionises the healthcare system by introducing a ‘humanisation’ of medical telemetry and e-health. This is done by improving the user experience of diagnostic measurements with an intuitive user interface.

The aim of the project is to develop a comprehensive, integrated e-solution. MESI mCARE (Home) will be available on the market no later than 31 August 2023 and will have a direct impact on the elimination and management of the consequences of COVID-19.

The result of the operation will be a product consisting of a combination of key breakthrough features of the final solution, namely:

• sensors for performing diagnostic measurements beyond basic medical standards;
• integration of AI, machine learning and automation;
• a medical device with as many as 4 algorithms;
• the furthering of digitalisation;
• photonics and electronics.

The solution will allow the user to measure the following diagnostic parameters:

• upper arm blood pressure,
• spirometry,
• average blood pressure,
• oximetry,
• 12-lead ECG,
• heart rate.

The investment is co-financed by the Republic of Slovenia and the European Union through the European Regional Development Fund in the amount of EUR 199,966.66. The operation takes place within the framework of the Operational Programme for the Implementation of the EU Cohesion Policy in the period 2014 – 2020.

The project is implemented by 2 partners: MESI, development of medical devices, Ltd., as lead partner, and Gigodesign 3, oblikovanje, design in strategije, d.o.o., as consortium partner.

More info at www.eu-skladi.si